They have also been useful to provide evidence for the effectiveness of combination therapy with lenalidomide prior to phase 3 trials (in previously lenalidomide/bortezomib resistant MM) [101] and ATRA via upregulation of CD38 expression [102, 103]. Here, CD38 is linked to Miyoshi myopathy.